Prevalence of Metabolic Syndrome and Its Components Among Men With and Without Clinical Benign Prostatic Hyperplasia: A Large, Cross-Sectional, UK Epidemiological Study

    September 2015 in “ BJUI ”
    Julia DiBello, Christos V. Ioannou, Jonathan Rees, Benjamin Challacombe, Joe Maskell, Nurul Choudhury, Christof Kastner, Mike Kirby
    Image of study
    TLDR Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.
    In a 2015 cross-sectional UK epidemiological study involving two cohorts of 85,103 men aged 50 years or older, researchers found that men with clinical benign prostatic hyperplasia (BPH) had a 37% increased odds of having metabolic syndrome compared to matched controls without BPH. Specifically, 26.5% of men with BPH had metabolic syndrome versus 20.9% of controls. The study also revealed that men with BPH were more likely to have each component of metabolic syndrome, with odds ratios ranging from 1.2 to 1.8 for various components. The association between BPH and metabolic syndrome was also influenced by smoking and alcohol intake, but interestingly, higher PSA levels were linked to lower odds of metabolic syndrome. The study's cross-sectional nature meant it could not determine the causal relationship between BPH and metabolic syndrome, but it highlighted a significant association between the two conditions in the UK primary care population.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 76 results

      community Male pattern baldness, and mental health

      in Finasteride/Dutasteride  331 upvotes 10 months ago
      A 48-year-old man has been using minoxidil for 15 years and considered finasteride but stopped due to potential side effects. He is concerned about his mental health and the impact of hair loss on self-image, and he encourages support among men experiencing hair loss.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 3 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community Wtf have we been doing for the last 30 years

      in Treatment  526 upvotes 4 days ago
      Hair loss treatments like finasteride, minoxidil, and dutasteride work but have side effects. A permanent cure is still not available due to the complexity of hair loss and limited investment.

    Similar Research

    5 / 1000+ results